NCT01426854

Nepafenac Compared to Placebo for Ocular Pain and Inflammation

Clinical Evaluation of Safety and Efficacy of Nepafenac Ophthalmic Suspension, 0.1% Compared to Placebo for the Prevention and Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery in Adult Chinese Subjects

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 260 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to demonstrate that Nepafenac Ophthalmic Suspension, 0.1% is superior to Nepafenac Vehicle (placebo) for the prevention and treatment of ocular inflammation and pain associated with cataract surgery in Chinese subjects.

Conditions

• Cataract

Interventions

Type	Name	Description
DRUG	Nepafenac Ophthalmic Suspension, 0.1%	Topical ocular administration
OTHER	Nepafenac Vehicle Ophthalmic Solution	Inactive ingredients used as placebo; topical ocular administration

Timeline

• Start date: 2011-07-01
• Primary completion: 2012-04-01
• Completion: 2012-04-01
• First posted: 2011-09-01
• Last updated: 2013-05-13
• Results posted: 2013-05-13

Locations

1 site across 1 country: China